Cybin Inc. (CYBN) has announced that its U.S. stock will be transferred from NYSE American to the Nasdaq Global Market, with the new ticker symbol HELP. The transfer will become effective on January 5 2026, after which the company’s shares will cease trading on NYSE American on the close of business on January 4 2026.
The move is part of Cybin’s strategy to align its public market presence with its growth trajectory. Nasdaq’s reputation as a technology‑ and biotechnology‑focused exchange is expected to improve liquidity and visibility among institutional investors who favor Nasdaq listings, potentially enhancing the company’s access to capital and market depth.
Cybin remains a clinical‑stage biopharmaceutical company with no revenue and significant operating losses, but it has strong liquidity and a robust cash position following a $175 million registered direct offering completed in October 2025. The company’s pipeline includes CYB003, a Phase 3 program for major depressive disorder that has received Breakthrough Therapy Designation, and CYB004, a Phase 2 program for generalized anxiety disorder. These assets underpin Cybin’s long‑term growth prospects and justify the strategic shift to a more biotech‑aligned exchange.
Interim CEO Eric So emphasized that the listing transfer “underscores confidence in our science and the differentiation of our therapeutic candidates.” He added that the recent financing “enables us to maintain strong momentum as we advance our Phase 2 and Phase 3 trials toward key data readouts in 2026 and work to deliver meaningful clinical outcomes closer to patients in need.”
The announcement has been received positively by investors, reflecting confidence in Cybin’s pipeline and the anticipated benefits of Nasdaq’s investor base, though no significant analyst upgrades or downgrades have been reported.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.